 |
|
|
 |
|
New Type 2 Diabetes Drug Delays Disease Progression
|
 |  |  |  | Related Healthscout Videos |  |
|
Page: << Prev | 1 | 2 | 3 And not only did Avandia have cardiovascular effects, it did so even though patients in this group were taking more of the cholesterol-lowering drugs known as statins because the drug appeared to raise their LDL ("bad") cholesterol, Nissen said.
Avandia seems clearly superior to Micronase, but the distinction between Avandia and Glucophage is less clear.
"In my opinion, the use of [Micronase] for any reason other than cost is going to become harder to justify," said Kahn, associate chief of staff for research at Veterans Affairs Puget Sound Health Care System and professor of medicine at the University of Washington, Seattle. "On the other hand, when you compare [Glucophage] and [Avandia], this is where it starts to become a little grayer... A lot more has to be done in terms of human investigation."
Text Continues Below

Overall, it's still not clear how physicians should treat patients.
"We're being inundated by medications, and we're being overwhelmed by patients who are not controlled by either one or even two medications. So, we're really talking about a condition that's going to be treated with multiple medications," said Dr. Stuart Weiss, clinical assistant professor of medicine at New York University School of Medicine. "The only thing that we can say is that combination therapy might be the best way to go from the beginning, and this study doesn't even address that."
More information
For more about type 2 diabetes, visit the National Diabetes Information Clearinghouse (diabetes.niddk.nih.gov ).
Page: << Prev | 1 | 2 | 3
|
Copyright © 2006 ScoutNews, LLC. All rights reserved.
Last updated 12/4/2006
|
 |

SOURCES: Steven E. Kahn, M.B., C.B., associate chief of staff, research, Veterans Affairs Puget Sound Health Care System, and professor, medicine, University of Washington, Seattle; Robert Rizza, M.D., past president, American Diabetes Association, and professor, medicine, Mayo Clinic College of Medicine, Rochester, Minn.; Steven E. Nissen, M.D., chairman, department of cardiovascular medicine, Cleveland Clinic, and president-elect, American College of Cardiology; Stuart Weiss, M.D., endocrinologist, New York University Medical Center and clinical assistant professor, NYU School of Medicine, New York City; Dec. 7, 2006, New England Journal of Medicine
|